1-10 of 10
Donald Kufe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B089: MUC1-C is a common driver of acquired osimertinb resistance in NSCLC

Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Ayako Nakashoji, Hideko Isozaki, Aaron Hata, Donald Kufe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B089.
https://doi.org/10.1158/1535-7163.TARG-23-B089
Published: 01 December 2023
View article titled, Abstract B089: MUC1-C is a common driver of acquired osimertinb resistance in NSCLC
Journal Articles

Abstract P027: MUC1-C integrates chronic activation of the type I and II interferon pathways in treatment resistance of triple-negative breast cancer

Nami Yamashita, Atsushi Fushimi, Yoshihiro Morimoto, Atrayee Bhattacharya, Mark Long, Song Liu, Donald Kufe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P027.
https://doi.org/10.1158/1535-7163.TARG-21-P027
Published: 01 December 2021
View article titled, Abstract P027: MUC1-C integrates chronic activation of the type I and II interferon pathways in treatment resistance of triple-negative breast cancer
Journal Articles

Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer

Tsuyoshi Hata, Hasan Rajabi, Masaaki Yamamoto, Caining Jin, Rehan Ahmad, Yan Zhang, Ling Kui, Wei Li, Yota Yasumizu, Deli Hong, Masaaki Miyo, Masayuki Hiraki, Takahiro Maeda, Yozo Suzuki, Hidekazu Takahashi, Mehmet Samur, Donald Kufe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (10): 1744–1754.
https://doi.org/10.1158/1535-7163.MCT-19-0156
Published: 01 October 2019
View article titled, Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer
Open the PDF for Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma

Salvia Jain, Abigail Washington, Rebecca Karp Leaf, Parul Bhargava, Rachael A. Clark, Thomas S. Kupper, Dina Stroopinsky, Athalia Pyzer, Leandra Cole, Myrna Nahas, Arie Apel, Jacalyn Rosenblatt, Jon Arnason, Donald Kufe, David Avigan
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (10): 2304–2314.
https://doi.org/10.1158/1535-7163.MCT-17-0060
Published: 02 October 2017
View article titled, Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma
Open the PDF for Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells

Deepak Raina, Michio Kosugi, Rehan Ahmad, Govind Panchamoorthy, Hasan Rajabi, Maroof Alam, Takeshi Shimamura, Geoffrey I. Shapiro, Jeffrey Supko, Surender Kharbanda, Donald Kufe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (5): 806–816.
https://doi.org/10.1158/1535-7163.MCT-10-1050
Published: 08 May 2011
View article titled, Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Open the PDF for Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells in another window
Includes: Supplementary data
Journal Articles

MUC1 oncoprotein is a druggable target in human prostate cancer cells

Maya Datt Joshi, Rehan Ahmad, Li Yin, Deepak Raina, Hasan Rajabi, Glenn Bubley, Surender Kharbanda, Donald Kufe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (11): 3056–3065.
https://doi.org/10.1158/1535-7163.MCT-09-0646
Published: 10 November 2009
View article titled, MUC1 oncoprotein is a druggable target in human prostate cancer cells
Open the PDF for MUC1 oncoprotein is a druggable target in human prostate cancer cells in another window
Includes: Supplementary data
Journal Articles

Phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies

David Hong, Razelle Kurzrock, Jeffrey Supko, Donald Lawrence, Jennifer Wheeler, Joseph Eder, Chaan Ng, James Mier, Marina Konopleva, Sergej Konoplev, Suhendan Ekmekcioglu, Michael Andreeff, Elizabeth Grimm, Donald Kufe, Colin Meyer, Geoffrey Shapiro, Bruce Dezube
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B82.
Published: 01 November 2007
View article titled, Phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies
Journal Articles

Novel compounds with antiproliferative activity against imatinib-resistant cell lines

Enrica I. Lerma, Viet-Anh Nguyen, Tao Wang, Alex Tipping, Junia V. Melo, Donald Kufe, David J. Austin, Albert Deisseroth
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (2): 655–666.
https://doi.org/10.1158/1535-7163.MCT-04-0307
Published: 16 February 2007
View article titled, Novel compounds with antiproliferative activity against imatinib-resistant cell lines
Open the PDF for Novel compounds with antiproliferative activity against imatinib-resistant cell lines in another window
Journal Articles

Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid

Takashi Ikeda, Yukiko Nakata, Fumihiko Kimura, Ken Sato, Kenneth Anderson, Kazuo Motoyoshi, Michael Sporn, Donald Kufe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (1): 39–45.
https://doi.org/10.1158/1535-7163.39.3.1
Published: 28 January 2004
View article titled, Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid
Open the PDF for Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid in another window
Journal Articles

The Novel Isocoumarin 2-(8-Hydroxy-6-methoxy-1-oxo-1H -2-benzopyran-3-yl) Propionic Acid (NM-3) Induces Lethality of Human Carcinoma Cells by Generation of Reactive Oxygen Species

Li Yin, Tsuneya Ohno, Ralph Weichselbaum, Surender Kharbanda, Donald Kufe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2001) 1 (1): 43–48.
Published: 01 November 2001
View article titled, The Novel Isocoumarin 2-(8-Hydroxy-6-methoxy-1-oxo-1<em>H</em> -2-benzopyran-3-yl) Propionic Acid (NM-3) Induces Lethality of Human Carcinoma Cells by Generation of Reactive Oxygen Species
Open the PDF for The Novel Isocoumarin 2-(8-Hydroxy-6-methoxy-1-oxo-1<em>H</em> -2-benzopyran-3-yl) Propionic Acid (NM-3) Induces Lethality of Human Carcinoma Cells by Generation of Reactive Oxygen Species in another window